Captrust Financial Advisors Invests $3.92 Million in CeriBell (NASDAQ:CBLL)

Captrust Financial Advisors acquired a new position in CeriBell (NASDAQ:CBLL - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 151,441 shares of the company's stock, valued at approximately $3,919,000. Captrust Financial Advisors owned approximately 0.42% of CeriBell as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in CBLL. FMR LLC acquired a new position in CeriBell during the 4th quarter worth $128,120,000. ABG WTT Global Life Science Capital Partners GP Ltd acquired a new position in CeriBell in the fourth quarter worth $28,160,000. RA Capital Management L.P. acquired a new position in CeriBell in the fourth quarter worth $21,340,000. Vanguard Group Inc. acquired a new position in CeriBell in the fourth quarter worth $18,015,000. Finally, Board of Trustees of The Leland Stanford Junior University acquired a new position in CeriBell in the fourth quarter worth $16,143,000.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $33.00 price objective on shares of CeriBell in a report on Wednesday, February 26th. LADENBURG THALM/SH SH started coverage on CeriBell in a research note on Friday, April 4th. They issued a "buy" rating and a $32.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, CeriBell presently has a consensus rating of "Buy" and a consensus price target of $32.50.

Insiders Place Their Bets

In other CeriBell news, CEO Xingjuan Chao sold 5,700 shares of the business's stock in a transaction dated Thursday, April 17th. The shares were sold at an average price of $15.02, for a total value of $85,614.00. Following the sale, the chief executive officer now directly owns 746,451 shares in the company, valued at approximately $11,211,694.02. The trade was a 0.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last three months, insiders have sold 24,700 shares of company stock worth $372,434.

CeriBell Stock Down 3.3%

Shares of NASDAQ CBLL traded down $0.56 during midday trading on Tuesday, reaching $16.60. 291,812 shares of the company traded hands, compared to its average volume of 274,267. CeriBell has a 52 week low of $10.01 and a 52 week high of $32.75. The stock's 50-day moving average is $17.93.

CeriBell (NASDAQ:CBLL - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.07. The business had revenue of $20.49 million during the quarter, compared to the consensus estimate of $19.30 million. On average, sell-side analysts anticipate that CeriBell will post -2.46 earnings per share for the current fiscal year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.